Nathan Herrmann
Overview
Explore the profile of Nathan Herrmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
439
Citations
11210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Anita N, Herrmann N, Ryoo S, Major-Orfao C, Lin W, Kwan F, et al.
J Diabetes Complications
. 2024 Jul;
38(9):108826.
PMID: 39059187
Aims: This study examined serum cytochrome P450-soluble epoxide hydrolase (CYP450-sEH) oxylipins and depressive symptoms together in relation to cognitive performance in individuals with type 2 diabetes mellitus (T2DM). Methods: Clinically...
12.
Xiong L, Wood Alexander M, Cogo-Moreira H, Wu C, Eid M, Herrmann N, et al.
Geroscience
. 2024 Jul;
47(1):1061-1073.
PMID: 39023667
The purpose of this study was to investigate relationships between depressive symptoms, functional disability, and physical activity over time in community-dwelling older adults. The Religious Order Study and Rush Memory...
13.
McInerney B, Cross A, Alderman C, Bhat R, Boyd C, Brandt N, et al.
J Am Med Dir Assoc
. 2024 Jul;
25(9):105118.
PMID: 38950588
Objectives: To produce a consensus list of the top 10 signs and symptoms suggestive of adverse drug events (ADEs) for monitoring in residents of long-term care facilities (LTCFs) who use...
14.
Zeng L, Perin J, Gross A, Shade D, Lanctot K, Lerner A, et al.
Int J Geriatr Psychiatry
. 2024 Jun;
39(6):e6108.
PMID: 38858522
Objectives: To examine clinically important adverse events (AEs) associated with methylphenidate (MPH) treatment of apathy in Alzheimer's Disease (AD) versus placebo, including weight loss, vital signs, falls, and insomnia. Methods:...
15.
Patterson R, Brooks H, Mirjalili M, Rashidi-Ranjbar N, Zomorrodi R, Blumberger D, et al.
Cogn Neurodyn
. 2024 Jun;
18(3):795-811.
PMID: 38826646
Supplementary Information: The online version contains supplementary material available at 10.1007/s11571-023-09938-y.
16.
Gaur A, Gallagher D, Herrmann N, Chen J, Marzolini S, Oh P, et al.
J Geriatr Psychiatry Neurol
. 2024 May;
38(1):62-72.
PMID: 38757180
Background: Neurofilament Light Chain (NfL) is a biomarker of axonal injury elevated in mild cognitive impairment (MCI) and Alzheimer's disease dementia. Blood NfL also inversely correlates with cognitive performance in...
17.
Wong M, Kiss A, Herrmann N, Lanctot K, Gallagher D
Can J Psychiatry
. 2024 May;
69(9):708-716.
PMID: 38751067
Objective: Depression in later life is associated with a two-fold increased risk of dementia. It is not clear to what extent potentially modifiable risk factors account for this association. Method:...
18.
Brooks H, Wang W, Zomorrodi R, Blumberger D, Bowie C, Daskalakis Z, et al.
Transl Psychiatry
. 2024 Mar;
14(1):153.
PMID: 38503740
Whether individuals with mild cognitive impairment (MCI) and a history of major depressive disorder (MDD) are at a higher risk for cognitive decline than those with MCI alone is still...
19.
Kapustin D, Tumati S, Wong M, Herrmann N, Dixon R, Seitz D, et al.
Int J Geriatr Psychiatry
. 2024 Mar;
39(3):e6080.
PMID: 38497928
Background: Apathy and depression are common neuropsychiatric symptoms across neurodegenerative disorders and are associated with impairment in several cognitive domains, yet little is known about the influence of sex on...
20.
Marawi T, Zhukovsky P, Brooks H, Bowie C, Butters M, Fischer C, et al.
Am J Geriatr Psychiatry
. 2024 Feb;
32(7):867-878.
PMID: 38403532
Objectives: To identify data-driven cognitive profiles in older adults with remitted major depressive disorder (rMDD) with or without mild cognitive impairment (MCI) and examine how the profiles differ regarding demographic,...